secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANNKIND CORP (MNKD)
CIK:        0000899460
Form:       8-K
Filed at:   2022-05-25T23:59:59+00:00
Accession:  0001564590-22-021266
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Tyvaso DPI using MannKind's Technosphere platform; availability June 2022
--------------------------------------------------------------------------------

- Tyvaso DPI is second FDA-approved product using MannKind's Technosphere inhalation platform; first dry powder inhaled treatment for PAH and PH-ILD.
- Manufacturing of Tyvaso DPI underway at MannKind's Connecticut facility; product availability expected in June 2022.
- Commercial supply agreement with United Therapeutics runs through 2031; initially signed in August 2021.
- Tyvaso DPI uses dry powder formulation and Dreamboat inhaler technology from Afrezza; convenient alternative to liquid nebulization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899460/000156459022021266/0001564590-22-021266-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899460/000156459022021266/mnkd-8k_20220524.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-021266

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer